免疫抑制药与降糖药的药物相互作用研究进展

Research Advance in Drug-drug Interactions between Immunosuppressants and Antidiabetic Drugs

移植术后新发糖尿病(NODAT)是实体器官移植术后的常见并发症,常需予以降糖药治疗。器官移植术后需长期使用免疫抑制药预防排斥反应发生,而免疫抑制药具有治疗窗狭窄、个体差异大、药物相互作用广泛的特点,与降糖药合用可能因药物相互作用影响免疫抑制药和(或)降糖药的疗效。文中综述了免疫抑制药和降糖药的药物动力学特征以及它们之间的已明确报道和潜在的药物相互作用(DDIs),以期为临床合理用药提供建议。

New-onset diabetes after transplantation （NODAT） is one of the severe complications after solid organ transplantation and often treated with antidiabetic drugs. Immunosuppressants used to prevent rejection after transplantation show narrow therapeutic index, large inter-individual variability and extensive drug interactions. Thus, concomitant with antidiabetic drugs and immunosuppres- sants may affect the efficacy resulting from drug-drug interactions （DDIs）. The review summarized the pharmacokinetic characteristics of immunosuppressants and antidiabetic drugs and the reported and potential DDIs between them to promote clinical rational drug use.